Evidence map›Paper›PMID 33342268›Full record

ArticleThe American surgeon2021

Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes.

Christof Kaltenmeier, Alison Althans, Maria Mascara, Ibrahim Nassour, Sidrah Khan, Richard Hoehn, Amer Zureikat, Samer Tohme

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American surgeon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Exercise and pathologic complete response to cancer treatment: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. PET-CT-based host metabolic (PETMet) features are associated with pathologic response in gastroesophageal adenocarcinoma.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Christof KaltenmeierDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Alison AlthansDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Maria MascaraDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Ibrahim NassourDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Sidrah KhanDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Richard HoehnDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Amer ZureikatDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
Samer TohmeDepartment of Surgery, 6614University of Pittsburgh, PA, USA.
University of Pittsburgh · US

Funding

Postdoctoral Research Training in Biotherapy of CancerT32CA113263 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Udai S Kammula · 2006 to 2026
$3.6M
NCI NIH HHS T32 CA113263
6 · The paper itself

Abstract

introductionWith advances in multimodal therapy, survival rates in gastric cancer have significantly improved over the last two decades. Neoadjuvant therapy increases the likelihood of achieving negative margins and may even lead to pathologic complete response (pCR). However, the impact of pCR on survival in gastric cancer has been poorly described. We analyzed the rate and predictors of pCR in patients receiving neoadjuvant therapy as well as impact of pCR on survival.

methodsWe conducted a National Cancer Database (NCDB) analysis (2004-2016) of patients with gastric adenocarcinoma who received neoadjuvant chemotherapy followed by surgical resection.

resultsThe pCR rate was 2.2%. Following adjustment, only neoadjuvant chemoradiation, non-signet histology, and tumor grade remained as significant factors predicting pCR. pCR was a statistically significant predictor of survival.

conclusionIn this NCDB study, pCR was a predictor of survival. Though chemoradiation rather than chemotherapy alone was a predictor of pCR, it was not a predictor of survival. Further studies are needed to elucidate the role of radiation in the neoadjuvant setting and to discern the impact of pCR on survival.

Indexed as

GastrectomyNeoadjuvant TherapyAdenocarcinomaAgedDatabases, FactualFemaleHumansIncidenceMaleMiddle AgedRisk FactorsStomach NeoplasmsSurvival RateTreatment OutcomeUnited Statesesophagus/foregutsurgical oncology

Identifiers

PMID33342268
PMCPMC8213860
OpenAlexW3118070642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.